You are here

CAR-T

Novartis still hasn't solved its lingering CAR-T manufacturing issues

Novartis still hasn't solved its lingering CAR-T manufacturing issues

Biopharma Dive

drug manufacturing

Flag link:

Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

Novartis Kymriah demonstrates consistent efficacy and safety outcomes in US patients when used in real-world setting

Pharmaceutical Business Review

Flag link:

ASH: Gilead touts 'astounding' Yescarta survival results at 3 years

ASH: Gilead touts 'astounding' Yescarta survival results at 3 years

Fierce Pharma

Gilead Sciences

refractory large B-cell lymphoma

Flag link:

2 Small-Cap Biotechs That Soared Last Week

2 Small-Cap Biotechs That Soared Last Week

Motley Fool

Magenta Therapeutics

Molecular Templates

Flag link:

Celgene posts pivotal CAR-T data ahead of FDA filing

Celgene posts pivotal CAR-T data ahead of FDA filing

Fierce Biotech

Flag link:

CAR-T cells as 'bait' show promise in autoimmune disease

CAR-T cells as 'bait' show promise in autoimmune disease

Fierce Biotech

autoimmune disease

Flag link:

Italian gene therapy player draws new investor from China for its answer to CAR-T relapses

Italian gene therapy player draws new investor from China for its answer to CAR-T relapses

Endpoints

Genenta Science

clinical trials

Multiple Myeloma

Flag link:

Trying to turn 'natural killers' against cancer, Nkarta raises $114 million

Trying to turn 'natural killers' against cancer, Nkarta raises $114 million

Bizjournals

Nkarta Therapeutics

natural killer cells

Flag link:

Achilles raises £100M for personalized T cell solid tumor trials

Achilles raises £100M for personalized T cell solid tumor trials

Fierce Biotech

Achilles Therapeutics

Flag link:

Autolus drags on Arix after weak period for CAR-T player

Autolus drags on Arix after weak period for CAR-T player

Fierce Biotech

Autolus Therapeutics

Arix Bioscience

Flag link:

Revealing the true value of new cancer drugs to payers

Revealing the true value of new cancer drugs to payers

Pharmaforum

Flag link:

Autolus delays multiple CAR-T clinical programs

Autolus delays multiple CAR-T clinical programs

Fierce Biotech

Flag link:

CMS to cover CAR-T therapy nationwide

CMS to cover CAR-T therapy nationwide

Beckers Hospital Review

Flag link:

A personalized CAR-T to attack every solid tumor? Pact Pharma has a plan

A personalized CAR-T to attack every solid tumor? Pact Pharma has a plan

Fierce Biotech

personalized medicine

Flag link:

Precision BioSciences backs off-the-shelf cancer cell therapy effort with new manufacturing plant

Precision BioSciences backs off-the-shelf cancer cell therapy effort with new manufacturing plant

Endpoints

Precision Biosciences

drug manufacturing

Flag link:

Biotech building facility to make genome-edited, off-the-shelf CAR-T therapies

Biotech building facility to make genome-edited, off-the-shelf CAR-T therapies

Fierce Pharma

Precision Biosciences

drug manufacturing

Flag link:

Takeda Receives 1st Stem Cell-Derived CAR-T From Kyoto University Collaboration

Takeda Receives 1st Stem Cell-Derived CAR-T From Kyoto University Collaboration

BioSpace

Kyoto University

Flag link:

Gilead's Kite builds cell therapy manufacturing quickly even as Yescarta sales grow slowly

Gilead's Kite builds cell therapy manufacturing quickly even as Yescarta sales grow slowly

Fierce Pharma

Gilead Sciences

Flag link:

Boosting CAR-T to treat solid tumors with a vaccine

Boosting CAR-T to treat solid tumors with a vaccine

Fierce Biotech

cancer vaccines

Flag link:

Are Natural Killer Cells the Next Big Thing in Immunotherapy?

Are Natural Killer Cells the Next Big Thing in Immunotherapy?

Motley Fool

NK immunotherapies

Flag link:

Pages